23 completed, 16 recruiting, 7 terminated, 5 unknown. 20 Phase 2, 9 Not applicable, 9 Phase 1, 4 Phase 3, 3 Phase 4.
Follow Focal Segmental Glomerulosclerosis: new trials by email Literature Review of Focal Segmental Glomerulosclerosis trials Research Report on Focal Segmental Glomerulosclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change Disease Sibeprenlimab - Primary Membranous Nephropathy, Minimal Change Disease | Phase 2 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 20 | 2026-12-15 | 2026-10-06 |
| An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases ManNAc - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | National Human Genome Research Institute (NHGRI) | 30 | 2026-10-27 | 2026-10-30 |
| A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) BI 764198, Placebo - Focal Segmental Glomerulosclerosis | Phase 3 | Recruiting | Boehringer Ingelheim | 286 | 2026-02-16 | 2026-10-28 |
| A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) Praliciguat (Part A), Placebo (Part A), Praliciguat (Part B) - Focal Segmental Glomerulosclerosis | Phase 2 | Recruiting | Akebia Therapeutics | 60 | 2025-12-03 | 2026-10-01 |
| Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis Sparsentan - Proteinuria, Immunoglobulin A (IgA) Nephropathy | Phase 4 | Active not recruiting | Travere Therapeutics, Inc. | 20 | 2025-10-07 | 2026-06-23 |
| A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease frexalimab, brivekimig, rilzabrutinib - Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion | Phase 2 | Recruiting | Sanofi | 84 | 2024-12-19 | 2026-10-19 |
| Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1 Nephrotic Syndrome, Focal Segmental Glomerulosclerosis | Unknown | Assistance Publique - Hôpitaux de Paris | 124 | 2024-06-30 | 2024-06-05 | |
| AMPK-activation by Metformin in FSGS: AMP-FSGS Metformin + Standard of Care, Placebo + Standard of Care - Focal Segmental Glomerulosclerosis | Phase 1 / Phase 2 | Recruiting | Yale University | 30 | 2023-12-14 | 2026-02-03 |
| A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects HS-10390 tablet, Placebo tablet - IgA Nephropathy, Focal Segmental Glomerulosclerosis | Phase 1 | Recruiting | Hansoh BioMedical R&D Company | 84 | 2023-05-23 | 2024-10-09 |
| taVNS for FRNS in Children Transcutaneous auricular vagus nerve stimulation, Sham device - Nephrotic Syndrome in Children, Minimal Change Disease | Not applicable | Recruiting | Northwell Health | 30 | 2023-01-05 | 2026-04-15 |
| ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank Registry - Focal Segmental Glomerulosclerosis, Proteinuria | Recruiting | Christoph Aufricht | 100 | 2023-01-01 | 2023-12-08 | |
| Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease Biospecimen collection, Data collection - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Recruiting | University of Michigan | 300 | 2022-12-08 | 2026-04-29 | |
| A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS) trascutaneous auricular vagus nerve stimulation, Sham device - Nephrotic Syndrome in Children, Minimal Change Disease | Not applicable | Recruiting | Northwell Health | 10 | 2022-09-19 | 2026-04-17 |
| Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis R3R01 - Alport Syndrome, Focal Segmental Glomerulosclerosis | Phase 2 | Completed | River 3 Renal Corp. | 43 | 2022-06-15 | 2025-09-29 |
| Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) VB119 - Minimal Change Disease, Focal Segmental Glomerulosclerosis | Phase 2 | Terminated | Tenet Medicines | 1 | 2022-05-03 | 2024-04-22 |
| NEPTUNE Match Study Communication - Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis | Not applicable | Recruiting | University of Michigan | 375 | 2022-05-02 | 2026-06-10 |
| Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy) Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy | Completed | Travere Therapeutics, Inc. | 487 | 2022-02-05 | 2024-02-21 | |
| Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases Sparsentan - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | Travere Therapeutics, Inc. | 67 | 2021-08-12 | 2026-05-12 |
| Atrasentan in Patients With Proteinuric Glomerular Diseases Atrasentan - IgA Nephropathy, Focal Segmental Glomerulosclerosis | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 103 | 2021-03-15 | 2026-06-01 |
| Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System LIPOSORBER® LA-15 - Focal Segmental Glomerulosclerosis | Not applicable | Recruiting | Kaneka Medical America LLC | 35 | 2020-01-01 | 2026-08-28 |
Showing 20 of 56. Sign in to see all of them.
Glomerulosclerosis, Focal Segmental (56) · Nephrosis, Lipoid (20) · Proteinuria (11) · Nephrotic Syndrome (10) · Glomerulonephritis, IGA (8) · Kidney Diseases (8) · Glomerulonephritis, Membranous (5) · Macular dystrophy, corneal type 1 (5) · Nephritis, Hereditary (5) · Renal Insufficiency, Chronic (4) · Diabetic Nephropathies (3) · AIDS-Associated Nephropathy (2) · Polycystic Kidney, Autosomal Dominant (2) · Recurrence (2) · Adenine phosphoribosyltransferase deficiency (1)
Female Urogenital Diseases (56) · Female Urogenital Diseases and Pregnancy Complications (56) · Male Urogenital Diseases (56) · Nephritis (56) · Urogenital Diseases (56) · Urologic Diseases (56) · Glomerulonephritis (55) · Kidney Diseases (48) · Nephrosis (24) · Pathological Conditions, Signs and Symptoms (19) · Immune System Diseases (13) · Signs and Symptoms (12) · Urination Disorders (12) · Autoimmune Diseases (11) · Pathologic Processes (11)
Galactose (4) · sparsentan (4) · Adalimumab (2) · CCX140-B (2) · Irbesartan (2) · Plasmapheresis (2) · Prednisone (2) · Rituximab (2) · Abatacept (1) · Atorvastatin (1) · Atrasentan (1) · Bone Marrow Purging (1) · Cyclophosphamide (1) · Data Collection (1) · Glucose (1)
Northwell Health (5) · Travere Therapeutics, Inc. (5) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · University of Michigan (3) · Amgen (2) · Istanbul University (2) · Kaneka Medical America LLC (2) · Akebia Therapeutics (1) · Assistance Publique - Hôpitaux de Paris (1) · Aurinia Pharmaceuticals Inc. (1) · Beth Israel Deaconess Medical Center (1) · Biogen (1) · Boehringer Ingelheim (1) · Bristol-Myers Squibb (1) · Children's Hospital Medical Center, Cincinnati (1)
United States (38) · United Kingdom (9) · Italy (8) · Germany (7) · Australia (6) · Canada (6) · France (6) · Spain (6) · China (5) · Netherlands (5) · Poland (5) · Belgium (4) · Brazil (4) · South Korea (4) · Turkey (Türkiye) (4)
Howard Trachtman, MD (3) · Radko Komers, MD, PhD (3) · Jeffrey B Kopp, M.D. (2) · Anirban Ganguli, M.D. (1) · Asha Moudgil, MD (1) · Baosong Gui, MD (1) · Cijiang He (1) · Debbie Gipson, MD (1) · Deborah Mensch, M.D. (1) · Dong Ki Kim, MD, PhD (1) · Eloise Salmon, MD (1) · Halil Yazici, MD (1) · Hamid Gourabi, PhD (1)
PMID 35224732, PMID 38724717, PMID 40337980, PMID 40938675, PMID 35230699, PMID 37254256, PMID 39899371, PMID 19073787, PMID 19932542, PMID 21310077, PMID 22995802, PMID 26198842, PMID 30361325, PMID 32842999, PMID 36657027, PMID 37675355, PMID 37921461, PMID 38831932, PMID 39015674, PMID 39808779, PMID 41433094, PMID 41442197, PMID 41630898, PMID 42384439
R01DK131091 (2), 2015 (1), 2025 (1), 5RC2DK122397 (1), R01DK141114 (1), R33DK070341 (1), U54DK083912 (1)